- Home
- KNSA
as 04-18-2025 1:38pm EST
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
| Founded: | 2015 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 1.5B | IPO Year: | 2018 |
| Target Price: | $37.17 | AVG Volume (30 days): | 638.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.56 - $28.15 | Next Earning Date: | 04-29-2025 |
| Revenue: | $423,239,000 | Revenue Growth: | 56.60% |
| Revenue Growth (this year): | 37.21% | Revenue Growth (next year): | 2.58% |
Stock Insider Trading Activity of Kiniksa Pharmaceuticals Ltd. (KNSA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Apr 14 '25 | Sell | $20.47 | 12,000 | $245,811.55 | 83,784 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Mar 20 '25 | Sell | $23.11 | 15,944 | $368,465.84 | 23,382 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Mar 16 '25 | Sell | $23.10 | 20,343 | $469,923.30 | 23,382 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Mar 12 '25 | Sell | $22.25 | 36,372 | $809,277.00 | 23,382 | |
| Megna Michael R | KNSA | CHIEF ACCOUNTING OFFICER | Mar 12 '25 | Sell | $22.45 | 9,051 | $203,194.95 | 26,528 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Mar 10 '25 | Sell | $21.06 | 12,409 | $261,333.54 | 83,784 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Feb 10 '25 | Sell | $19.57 | 14,000 | $273,980.00 | 83,784 |
Latest Kiniksa Pharmaceuticals Ltd. News
KNSA Breaking Stock News: Dive into KNSA Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar?
Zacks
11 days ago
Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?
Zacks
15 days ago
Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Here's What You Should Know
Zacks
a month ago
How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6%
Motley Fool
a month ago
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
MT Newswires
a month ago
Citigroup Initiates Coverage on Kiniksa Pharmaceuticals International With Buy Rating, $40 Price Target
Insider Monkey
a month ago
Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best UK Growth Stock to Buy Now?
Zacks
2 months ago
Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock
Compare KNSA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KNSA Kiniksa Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.